Literature DB >> 8980781

Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia.

F S Nolte1, T Parkinson, D J Falconer, S Dix, J Williams, C Gilmore, R Geller, J R Wingard.   

Abstract

Infections with fluconazole-resistant Candida albicans isolate have rarely been described in clinical settings other than oropharyngeal candidiasis in patients with late-stage AIDS. We report on two patients with leukemia who developed fungemia caused by fluconazole-resistant C. albicans after receiving fluconazole prophylaxis (400 mg/day) and empiric amphotericin B therapy (0.5 mg/kg of body weight per day). The fluconazole MICs for the isolates were > or = 64 micrograms/ml, and the isolates were resistant to other azoles and had membrane sterol changes consistent with a mutation in the delta 5,6-sterol desaturase gene. The lack of ergosterol in the cytoplasmic membrane of the fluconazole-resistant strains also imparted resistance to amphotericin B. Both patients were successfully treated with high-dose amphotericin B (1 to 1.25 mg/kg/day) and flucytosine (150 mg/kg/day).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8980781      PMCID: PMC163686     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  A comparison of the sterol content of multiple isolates of the Candida albicans Darlington strain with other clinically azole-sensitive and -resistant strains.

Authors:  S A Howell; A I Mallet; W C Noble
Journal:  J Appl Bacteriol       Date:  1990-11

Review 2.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 3.  Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; D Bellens; H Moereels; P A Janssen
Journal:  Biochem Soc Trans       Date:  1990-02       Impact factor: 5.407

4.  Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.

Authors:  J R Wingard; W G Merz; M G Rinaldi; T R Johnson; J E Karp; R Saral
Journal:  N Engl J Med       Date:  1991-10-31       Impact factor: 91.245

5.  Detection of amphotericin B-resistant Candida isolates in a broth-based system.

Authors:  J H Rex; C R Cooper; W G Merz; J N Galgiani; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

6.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.

Authors:  J L Goodman; D J Winston; R A Greenfield; P H Chandrasekar; B Fox; H Kaizer; R K Shadduck; T C Shea; P Stiff; D J Friedman
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

7.  Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients.

Authors:  J R Wingard; W G Merz; M G Rinaldi; C B Miller; J E Karp; R Saral
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period.

Authors:  M F Price; M T LaRocco; L O Gentry
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Genomic heterogeneity in the yeast Candida parapsilosis.

Authors:  T J Lott; R J Kuykendall; S F Welbel; A Pramanik; B A Lasker
Journal:  Curr Genet       Date:  1993 May-Jun       Impact factor: 3.886

10.  Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata.

Authors:  T Parkinson; D J Falconer; C A Hitchcock
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

View more
  69 in total

Review 1.  Fungal resistance.

Authors:  H Bernhardt; K Zimmermann; M Knoke
Journal:  Infection       Date:  1999       Impact factor: 3.553

Review 2.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

3.  Transcriptional analyses of antifungal drug resistance in Candida albicans.

Authors:  C N Lyons; T C White
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  T J Walsh; C E Gonzalez; S Piscitelli; J D Bacher; J Peter; R Torres; D Shetti; V Katsov; K Kligys; C A Lyman
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

5.  Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus.

Authors:  Paul Bowyer; Juan Mosquera; Michael Anderson; Mike Birch; Michael Bromley; David W Denning
Journal:  FEMS Microbiol Lett       Date:  2012-05-21       Impact factor: 2.742

Review 6.  Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

7.  Efg1 involved in drug resistance by regulating the expression of ERG3 in Candida albicans.

Authors:  Hsiu-Jung Lo; Jang-Shiun Wang; Chih-Yang Lin; Chia-Geun Chen; Ting-Yin Hsiao; Chia-Tung Hsu; Chia-Li Su; Ming-Ji Fann; Yu-Tai Ching; Yun-Liang Yang
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

8.  Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans.

Authors:  D Andes; A Forrest; A Lepak; J Nett; K Marchillo; L Lincoln
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 9.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

10.  In vitro and in vivo effects of 14alpha-demethylase (ERG11) depletion in Candida glabrata.

Authors:  H Nakayama; N Nakayama; M Arisawa; Y Aoki
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.